Generation of Induced Pluripotent Stem Cells from Turner Syndrome (45XO) Fetal Cells for Downstream Modelling of Neurological Deficits Associated with the Syndrome
December 4th, 2021
2.6K views
This protocol describes the generation of integration free iPSCs from fetal tissue fibroblasts through delivery of episomal plasmids by nucleofection followed by description of methods used for iPSC characterization and neuronal differentiation.
Overview
This protocol outlines the generation of integration-free induced pluripotent stem cells (iPSCs) from fetal tissue fibroblasts using episomal plasmids delivered by nucleofection. It also describes methods for iPSC characterization and neuronal differentiation.
Key Study Components
Area of Science
- Stem Cell Biology
- Neuroscience
- Cell Differentiation
Background
- Turner syndrome is characterized by a missing X chromosome and associated with various health issues.
- Somatic cells from aneuploid fetuses are valuable for research but have limited lifespan.
- Induced pluripotent stem cells (iPSCs) provide a method for long-term conservation of aneuploid traits.
- iPSCs can differentiate into specialized cell types, mimicking early embryonic development.
Purpose of Study
- To generate integration-free iPSCs from fetal tissue fibroblasts.
- To characterize the generated iPSCs.
- To differentiate iPSCs into neuronal cells.
Methods Used
- Delivery of episomal plasmids via nucleofection.
- Characterization of iPSCs through various assays.
- Neuronal differentiation protocols.
- Analysis of differentiation efficiency and cell viability.
Main Results
- Successful generation of integration-free iPSCs from fibroblasts.
- Characterization confirmed pluripotency of the iPSCs.
- Efficient differentiation into neuronal cells was achieved.
- Potential applications in studying Turner syndrome and related conditions.
Conclusions
- This protocol provides a reliable method for generating iPSCs from fetal fibroblasts.
- Characterization and differentiation methods are effective for research purposes.
- iPSCs can be utilized for studying genetic disorders like Turner syndrome.
Frequently Asked Questions
What is Turner syndrome?
Turner syndrome is a genetic condition caused by a missing or incomplete X chromosome, leading to various health issues.
How are iPSCs generated from fibroblasts?
iPSCs are generated by delivering episomal plasmids into fibroblasts using nucleofection, allowing them to revert to a pluripotent state.
What are the applications of iPSCs?
iPSCs can be used for disease modeling, drug testing, and regenerative medicine, particularly in genetic disorders.
What methods are used to characterize iPSCs?
Characterization methods include assays for pluripotency markers and differentiation potential into various cell types.
Can iPSCs differentiate into neuronal cells?
Yes, iPSCs can be differentiated into neuronal cells, making them valuable for neuroscience research.
What is the significance of using integration-free iPSCs?
Integration-free iPSCs reduce the risk of genetic alterations and are safer for therapeutic applications.
Executive Industry Relevance
Generation of integration-free iPSCs from Turner syndrome fetal fibroblasts provides a renewable cellular resource for modeling neurocognitive deficits linked to X-chromosome monosomy. This approach enables mechanistic de-risking of neurodevelopmental pathways and supports target validation in preclinical discovery. The retained 45XO karyotype ensures disease-relevant phenotypic screening for therapeutic hypothesis interrogation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by modeling X-chromosome dosage effects on neurodevelopment.
- Operational Value: Provides a self-renewing source of disease-relevant cells for consistent target engagement studies.
- Predictive Value: Supports phenotypic screening of compounds for rescue of neurocognitive deficit-associated pathways.
Screening & Assay Development
- Scientific Value: Differentiated neurons express lineage-specific biomarkers (βIII tubulin) enabling quantitative assay readouts.
- Operational Value: Episomal plasmid loss by passage 15 ensures genotype stability for reproducible screening campaigns.
- Scalability: Embryoid body formation and trilineage differentiation support multi-well plate compatibility for assay miniaturization.
Translational & Preclinical Research
- Translational Continuity: Retained fetal karyotype allows modeling of early developmental events contributing to Turner syndrome neurocognitive phenotype.
- Mechanistic De-risking: Differentiation into endoderm, mesoderm, and ectoderm lineages enables pathway-specific target validation.
- Preclinical Model: Neuronal differentiation capacity supports evaluation of candidate modifiers of neurodevelopmental deficits.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing by providing a stable, genetically defined cellular platform.
- Discovery Biology: Supports hypothesis testing of X-chromosome-linked neurodevelopmental mechanisms via pluripotent state capture.
- Screening: Differentiated cells yield quantitative outputs (e.g., biomarker expression) for compound screening and structure-activity relationship analysis.
- Analytics: Pluripotency marker expression (OCT4, NANOG, SOX2, SSEA4, TRA1-81) enables lineage commitment tracking and differentiation efficiency scoring.
- Translational Research: Disease-relevant 45XO karyotype continuity allows biomarker-aligned preclinical validation of neurodevelopmental rescue strategies.
- Enterprise Reuse: Integration-free iPSCs establish a reusable biobank for longitudinal study of chromosomal disorder phenotypes across projects.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through retention of pathogenic chromosomal context.
- Operational Value: Standardized nucleofection and episomal reprogramming ensure reproducibility across cell batches and laboratories.
- Strategic Value: Reduced biological de-risking timelines by providing immediate access to stable, disease-relevant neuronal models.
- Portfolio Impact: Enables risk-adjusted advancement decisions by modeling neurodevelopmental deficit mechanisms early in discovery.
Implementation Considerations
- Requires expertise in stem cell culture, nucleofection techniques, and pluripotency characterization.
- Dependent on nucleofector equipment, episomal plasmid production, and specialized differentiation media.
- Necessitates standardization of karyotype verification and pluripotency scoring across teams.
- Adaptation to other aneuploid models requires validation of reprogramming efficiency and karyotype stability.
- Limited by fetal tissue availability and ethical sourcing constraints for primary cell isolation.
Biopharma FAQs
Why does karyotype retention matter for target validation in Turner syndrome models?
Retention of the original 45XO karyotype post-reprogramming ensures that modeled neurodevelopmental deficits reflect the chromosomal etiology of Turner syndrome, enabling credible target validation of X-chromosome-linked pathways.
How does episomal plasmid loss support assay reproducibility in iPSC-derived neuronal models?
Spontaneous loss of exogenous episomal plasmids by passage 15 eliminates transgene-induced variability, ensuring stable genotypes for consistent neuronal differentiation and screening outcomes.
What quantitative measurements enable predictive confidence in neurodevelopmental deficit modeling?
Expression of lineage-specific biomarkers such as βIII tubulin in differentiated neurons provides quantifiable readouts to assess rescue of neurodevelopmental phenotypes and compound efficacy.
Why are replication requirements critical for cross-functional collaboration in iPSC-based target validation?
Standardized reprogramming, characterization, and differentiation protocols allow independent replication of TSiPSC models across discovery, preclinical, and translational teams, ensuring data comparability.
What statistical analysis capabilities are required before implementing iPSC models for preclinical decision-making?
Analysis of pluripotency marker expression, trilineage differentiation efficiency, and neuronal biomarker quantification enables statistical comparison of experimental conditions and supports go/no-go criteria in target validation.
